BUB1 Activators
BUB1 activators are a class of chemicals that can modulate the activity of the BUB1 protein indirectly by influencing specific cellular processes and pathways. These chemicals, such as nocodazole, paclitaxel, roscovitine, monastrol, MLN8054, BI 2536, ZM447439, reversine, VX-680, and parthenolide, target various components of the cell cycle machinery, particularly those involved in mitotic progression and spindle assembly. The first group of BUB1 activators includes microtubule-targeting agents, such as nocodazole and paclitaxel. Nocodazole disrupts microtubule dynamics by binding to tubulin and inhibiting microtubule polymerization. This disruption leads to mitotic arrest and activates the spindle assembly checkpoint (SAC), where BUB1 plays a critical role. Similarly, paclitaxel stabilizes microtubules, resulting in mitotic arrest and SAC activation, eventually leading to BUB1 activation.
Another group of chemicals, including roscovitine, monastrol, MLN8054, BI 2536, ZM447439, reversine, and VX-680, target specific kinases involved in mitotic regulation. Roscovitine is a cyclin-dependent kinase (CDK) inhibitor that induces G2/M cell cycle arrest, triggering the SAC pathway and indirectly activating BUB1. Monastrol inhibits the mitotic kinesin Eg5, leading to monopolar spindles and SAC activation, subsequently activating BUB1. Inhibition of Aurora kinases, such as AURKA and AURKB, by MLN8054, BI 2536, ZM447439, reversine, and VX-680 induces mitotic arrest and SAC activation, eventually modulating BUB1 activity. Lastly, parthenolide, a natural compound, exhibits BUB1-activating properties. Although the exact mechanism is not fully elucidated, parthenolide has been shown to induce mitotic arrest and SAC activation, suggesting its indirect modulation of BUB1 function. Overall, BUB1 activators exert their influence on the BUB1 protein indirectly by targeting key components of the cell cycle machinery and mitotic regulation. Through their effects on microtubules, kinases, and cell cycle progression, these chemicals activate the SAC pathway, ultimately leading to the activation or modulation of BUB1.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
Nocodazole is a microtubule-disrupting agent that affects cell cycle progression. It binds to tubulin and inhibits microtubule polymerization, leading to mitotic arrest. This arrest activates the spindle assembly checkpoint (SAC), a pathway where BUB1 plays a crucial role as a key component. | ||||||
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $41.00 $74.00 $221.00 $247.00 $738.00 $1220.00 | 39 | |
Paclitaxel, also known as Taxol, is a microtubule-stabilizing agent. It promotes microtubule assembly and stability, leading to mitotic arrest. Similar to nocodazole, the mitotic arrest induced by paclitaxel triggers the SAC pathway, resulting in BUB1 activation. Paclitaxel's effect on microtubules indirectly influences BUB1 function by engaging the SAC-mediated checkpoint control of mitotic progression. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine, a cyclin-dependent kinase (CDK) inhibitor, can modulate BUB1 activity indirectly by affecting cell cycle progression. It specifically inhibits CDK1 and CDK2, leading to cell cycle arrest in the G2/M phase. This arrest activates the SAC pathway, where BUB1 plays a pivotal role. Therefore, roscovitine-induced G2/M arrest indirectly activates BUB1 by engaging the SAC-mediated checkpoint control of mitotic progression. | ||||||
Monastrol | 254753-54-3 | sc-202710 sc-202710A | 1 mg 5 mg | $120.00 $233.00 | 10 | |
Monastrol is a small molecule inhibitor that disrupts the function of the mitotic kinesin Eg5, a motor protein involved in spindle pole separation. By inhibiting Eg5, monastrol induces monopolar spindles and activates the SAC pathway, which subsequently activates BUB1. Monastrol's interference with spindle dynamics indirectly leads to the activation of BUB1 through the SAC checkpoint control. | ||||||
MLN 8054 | 869363-13-3 | sc-484828 | 5 mg | $398.00 | ||
MLN8054 is a selective small molecule inhibitor of Aurora kinase A (AURKA), an important regulator of mitotic entry and spindle assembly. MLN8054 treatment induces mitotic arrest by inhibiting AURKA, which triggers the SAC pathway and activates BUB1. The disruption of AURKA function indirectly modulates BUB1 activity through the SAC-mediated mitotic checkpoint control. | ||||||
BI 2536 | 755038-02-9 | sc-364431 sc-364431A | 5 mg 50 mg | $151.00 $525.00 | 8 | |
BI 2536 is a potent inhibitor of Polo-like kinase 1 (PLK1), a key regulator of multiple mitotic processes. Inhibition of PLK1 by BI 2536 leads to mitotic arrest and SAC activation, subsequently activating BUB1. BI 2536's impact on PLK1 indirectly influences BUB1 activity through the SAC checkpoint control of mitotic progression. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $153.00 $356.00 | 15 | |
ZM447439 is a selective inhibitor of Aurora kinase B (AURKB), a critical component of the chromosomal passenger complex involved in kinetochore-microtubule attachment and cytokinesis. Inhibition of AURKB by ZM447439 induces mitotic arrest and activates the SAC pathway, thereby activating BUB1. ZM447439's modulation of AURKB indirectly regulates BUB1 function through the SAC-mediated mitotic checkpoint control. | ||||||
Reversine | 656820-32-5 | sc-203236 | 5 mg | $221.00 | 13 | |
Reversine is a small molecule that can induce reversion of differentiated cells to a multipotent state. It inhibits Aurora kinases, including AURKA and AURKB, leading to mitotic arrest and SAC activation. This activation subsequently activates BUB1, as it is involved in the SAC pathway. Reversine's impact on Aurora kinases indirectly influences BUB1 activity through the SAC-mediated mitotic checkpoint control. | ||||||
Tozasertib | 639089-54-6 | sc-358750 sc-358750A | 25 mg 50 mg | $62.00 $87.00 | 4 | |
VX-680, also known as Tozasertib, is a potent inhibitor of multiple kinases, including Aurora kinases (AURKA and AURKB), ABL, and FLT3. Its inhibition of Aurora kinases induces mitotic arrest and activates the SAC pathway, which in turn activates BUB1. VX-680's modulation of Aurora kinases indirectly regulates BUB1 function through the SAC-mediated mitotic checkpoint control. | ||||||